GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jasper Therapeutics JSPR · USD

Health Care · US listing · 🇺🇸 United States

Compare

16.37

-2.91%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jasper Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Jasper Therapeutics is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker JSPR. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $75.8m. At that date it held total assets of $35.8m and shareholders' equity of $4.2m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
20 Nov 2019
Employees
35
Head office
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA, 94065
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Thomas WiggansNon-Executive Independent Chairman of the Board$231,489
  • Mr. Ronald MartellPresident, Chief Executive Officer, Director, since 2022$3.2m
  • Mr. Herb CrossChief Financial Officer, Corporate Secretary$1.3m
  • Mr. Jeetinder MahalChief Operating Officer$1.3m
  • Dr. Judith ShizuruDirector$457,789
  • Dr. Scott BrunIndependent Director$217,789
  • Mr. Vishal KapoorIndependent Director$212,989
  • Dr. Svetlana LucasIndependent Director$324,035
  • Mr. Christian NoletIndependent Director$226,489
  • Mr. Kurt Von EmsterIndependent Director$228,289

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
27
Environment
27
Social
39
Governance
16
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Jasper Therapeutics focuses on clinical-stage biotechnology with 35 employees in Redwood City.
  • Jasper Therapeutics' lead product briquilimab targets mast and stem cells for CSU and LR-MDS treatments.
  • Jasper Therapeutics develops mRNA stem cell platform for engineered hematopoietic stem cell therapies.

Weaknesses

  • Jasper Therapeutics has only 35 employees, which may limit research capacity.
  • Jasper Therapeutics' IPO was in 2019, indicating limited market history.
  • Jasper Therapeutics operates in a highly competitive biotechnology sector.

Opportunities

  • Jasper Therapeutics can expand its clinical trials for briquilimab in CSU and LR-MDS diseases.
  • Jasper Therapeutics may develop new applications for mRNA stem cell platform technology.
  • Jasper Therapeutics can seek partnerships for stem cell therapy commercialization.

Threats

  • Jasper Therapeutics faces regulatory challenges in biotechnology drug approvals.
  • Jasper Therapeutics must navigate high costs of clinical development for stem cell therapies.
  • Jasper Therapeutics risks competition from other biotech firms in hematopoietic stem cell therapy.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.